Kenneth Galbraith joins Profound Medical board

Kenneth Galbraith, an accomplished life sciences industry veteran, has been appointed a director of Profound Medical (TSX-V:PRN).

Mr. Galbraith has over 25 years of experience as an executive, director, investor and advisor to companies in the biotechnology, medical device, pharmaceutical and healthcare sectors.

He joined Ventures West as a general partner in 2007 and led the firm’s biotechnology practice prior to founding Five Corners Capital in 2013 to continue management of the Ventures West investment portfolio. Previously, he served as the chairman and Interim CEO of AnorMED until its sale to Genzyme, and also spent 13 years in senior management with QLT.

In a statement, Damian Lamb, chairman of Profound, said Mr. Galbraith has a strong track record of helping emerging life sciences companies develop into industry leaders.

Mr. Galbraith said he is looking forward to working with Profound’s leadership team to help the company realize its strong potential to become a valuable leader in prostate cancer care.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.